APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

GFAP Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global GFAP Antibody Market Outlook and Growth Opportunities 2026

Report ID 173995000419 December 2025193 pages

Choose your research edition.

Industry ResearchGFAP Antibody Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal GFAP Antibody Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal GFAP Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GFAP Antibody Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal GFAP Antibody Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global GFAP Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for GFAP Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for GFAP Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for GFAP Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the GFAP Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the GFAP Antibody market include Merck, Synaptic Systems, Sino Biological, Santa Cruz Biotechnology, Proteintech, ProSci, Miltenyi Biotec, Hytest and GeneTex, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global GFAP Antibody market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of GFAP Antibody and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents GFAP Antibody revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global GFAP Antibody market.

GFAP Antibody Segment by Company

Merck

Synaptic Systems

Sino Biological

Santa Cruz Biotechnology

Proteintech

ProSci

Miltenyi Biotec

Hytest

GeneTex

FineTest

Enzo Life Sciences

EnCor Biotechnology

Aviva Systems Biology

Atlas Antibodies

GFAP Antibody Segment by Type

Polyclonal

Monoclonal

GFAP Antibody Segment by Application

Immunohistochemistry Paraffin

Immunohistochemistry Frozen

Immunofluorescence

Western Blot

Others

GFAP Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global GFAP Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the GFAP Antibody key companies, revenue, market share, and recent developments.

3. To split the GFAP Antibody breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions GFAP Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify GFAP Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze GFAP Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GFAP Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GFAP Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GFAP Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global GFAP Antibody industry.

Chapter 3: Detailed analysis of GFAP Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of GFAP Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of GFAP Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. GFAP Antibody Industry Trends Table 2. GFAP Antibody Industry Drivers Table 3. GFAP Antibody Industry Opportunities and Challenges Table 4. GFAP Antibody Industry Restraints Table 5. Global GFAP Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global GFAP Antibody Revenue Share by Company (2021-2026) Table 7. Global GFAP Antibody Company Ranking, (2024-2026) & (US$ Million) Table 8. Global GFAP Antibody Key Company Manufacturing Base & Headquarters Table 9. Global GFAP Antibody Company, Product Type & Application Table 10. Global GFAP Antibody Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global GFAP Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Polyclonal Table 15. Significant Companies of Monoclonal Table 16. Global GFAP Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global GFAP Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global GFAP Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global GFAP Antibody Sales Value Share by Type (2021-2026) Table 20. Global GFAP Antibody Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Immunohistochemistry Paraffin Table 22. Significant Companies of Immunohistochemistry Frozen Table 23. Significant Companies of Immunofluorescence Table 24. Significant Companies of Western Blot Table 25. Significant Companies of Others Table 26. Global GFAP Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global GFAP Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global GFAP Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global GFAP Antibody Sales Value Share by Application (2021-2026) Table 30. Global GFAP Antibody Sales Value Share by Application (2027-2032) Table 31. Global GFAP Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global GFAP Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global GFAP Antibody Sales Value Share by Region (2021-2026) Table 34. Global GFAP Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global GFAP Antibody Sales Value Share by Region (2027-2032) Table 36. Global GFAP Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global GFAP Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global GFAP Antibody Sales Value Market Share by Country (2021-2026) Table 39. Global GFAP Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global GFAP Antibody Sales Value Market Share by Country (2027-2032) Table 41. Merck Company Information Table 42. Merck Business Overview Table 43. Merck GFAP Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Merck GFAP Antibody Product Portfolio Table 45. Merck Recent Development Table 46. Synaptic Systems Company Information Table 47. Synaptic Systems Business Overview Table 48. Synaptic Systems GFAP Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Synaptic Systems GFAP Antibody Product Portfolio Table 50. Synaptic Systems Recent Development Table 51. Sino Biological Company Information Table 52. Sino Biological Business Overview Table 53. Sino Biological GFAP Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Sino Biological GFAP Antibody Product Portfolio Table 55. Sino Biological Recent Development Table 56. Santa Cruz Biotechnology Company Information Table 57. Santa Cruz Biotechnology Business Overview Table 58. Santa Cruz Biotechnology GFAP Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Santa Cruz Biotechnology GFAP Antibody Product Portfolio Table 60. Santa Cruz Biotechnology Recent Development Table 61. Proteintech Company Information Table 62. Proteintech Business Overview Table 63. Proteintech GFAP Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Proteintech GFAP Antibody Product Portfolio Table 65. Proteintech Recent Development Table 66. ProSci Company Information Table 67. ProSci Business Overview Table 68. ProSci GFAP Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. ProSci GFAP Antibody Product Portfolio Table 70. ProSci Recent Development Table 71. Miltenyi Biotec Company Information Table 72. Miltenyi Biotec Business Overview Table 73. Miltenyi Biotec GFAP Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Miltenyi Biotec GFAP Antibody Product Portfolio Table 75. Miltenyi Biotec Recent Development Table 76. Hytest Company Information Table 77. Hytest Business Overview Table 78. Hytest GFAP Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Hytest GFAP Antibody Product Portfolio Table 80. Hytest Recent Development Table 81. GeneTex Company Information Table 82. GeneTex Business Overview Table 83. GeneTex GFAP Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. GeneTex GFAP Antibody Product Portfolio Table 85. GeneTex Recent Development Table 86. FineTest Company Information Table 87. FineTest Business Overview Table 88. FineTest GFAP Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. FineTest GFAP Antibody Product Portfolio Table 90. FineTest Recent Development Table 91. Enzo Life Sciences Company Information Table 92. Enzo Life Sciences Business Overview Table 93. Enzo Life Sciences GFAP Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Enzo Life Sciences GFAP Antibody Product Portfolio Table 95. Enzo Life Sciences Recent Development Table 96. EnCor Biotechnology Company Information Table 97. EnCor Biotechnology Business Overview Table 98. EnCor Biotechnology GFAP Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. EnCor Biotechnology GFAP Antibody Product Portfolio Table 100. EnCor Biotechnology Recent Development Table 101. Aviva Systems Biology Company Information Table 102. Aviva Systems Biology Business Overview Table 103. Aviva Systems Biology GFAP Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Aviva Systems Biology GFAP Antibody Product Portfolio Table 105. Aviva Systems Biology Recent Development Table 106. Atlas Antibodies Company Information Table 107. Atlas Antibodies Business Overview Table 108. Atlas Antibodies GFAP Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Atlas Antibodies GFAP Antibody Product Portfolio Table 110. Atlas Antibodies Recent Development Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. GFAP Antibody Product Image Figure 2. Global GFAP Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GFAP Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global GFAP Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Polyclonal Image Figure 8. Monoclonal Image Figure 9. Global GFAP Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global GFAP Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global GFAP Antibody Sales Value Share by Type (2021-2032) Figure 12. Immunohistochemistry Paraffin Image Figure 13. Immunohistochemistry Frozen Image Figure 14. Immunofluorescence Image Figure 15. Western Blot Image Figure 16. Others Image Figure 17. Global GFAP Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global GFAP Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global GFAP Antibody Sales Value Share by Application (2021-2032) Figure 20. Global GFAP Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global GFAP Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America GFAP Antibody Sales Value (2021-2032) & (US$ Million) Figure 23. North America GFAP Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe GFAP Antibody Sales Value (2021-2032) & (US$ Million) Figure 25. Europe GFAP Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific GFAP Antibody Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific GFAP Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America GFAP Antibody Sales Value (2021-2032) & (US$ Million) Figure 29. South America GFAP Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa GFAP Antibody Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa GFAP Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt GFAP Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt GFAP Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt GFAP Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Polyclonal
  • Monoclonal
Applications
  • Immunohistochemistry Paraffin
  • Immunohistochemistry Frozen
  • Immunofluorescence
  • Western Blot
  • Others
Companies covered
  • Merck
  • Synaptic Systems
  • Sino Biological
  • Santa Cruz Biotechnology
  • Proteintech
  • ProSci
  • Miltenyi Biotec
  • Hytest
  • GeneTex
  • FineTest
  • Enzo Life Sciences
  • EnCor Biotechnology
  • Aviva Systems Biology
  • Atlas Antibodies

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global GFAP Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global GFAP Antibody Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 GFAP Antibody Market Dynamics
  1. 2.1 GFAP Antibody Industry Trends
  2. 2.2 GFAP Antibody Industry Drivers
  3. 2.3 GFAP Antibody Industry Opportunities and Challenges
  4. 2.4 GFAP Antibody Industry Restraints
3 GFAP Antibody Market by Company
  1. 3.1 Global GFAP Antibody Company Revenue Ranking in 2025
  2. 3.2 Global GFAP Antibody Revenue by Company (2021-2026)
  3. 3.3 Global GFAP Antibody Company Ranking (2024-2026)
  4. 3.4 Global GFAP Antibody Company Manufacturing Base and Headquarters
  5. 3.5 Global GFAP Antibody Company Product Type and Application
  6. 3.6 Global GFAP Antibody Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global GFAP Antibody Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 GFAP Antibody Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 GFAP Antibody Market by Type
  1. 4.1 GFAP Antibody Type Introduction
  2. 4.1.1 Polyclonal
  3. 4.1.2 Monoclonal
  4. 4.2 Global GFAP Antibody Sales Value by Type
  5. 4.2.1 Global GFAP Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global GFAP Antibody Sales Value by Type (2021-2032)
  7. 4.2.3 Global GFAP Antibody Sales Value Share by Type (2021-2032)
5 GFAP Antibody Market by Application
  1. 5.1 GFAP Antibody Application Introduction
  2. 5.1.1 Immunohistochemistry Paraffin
  3. 5.1.2 Immunohistochemistry Frozen
  4. 5.1.3 Immunofluorescence
  5. 5.1.4 Western Blot
  6. 5.1.5 Others
  7. 5.2 Global GFAP Antibody Sales Value by Application
  8. 5.2.1 Global GFAP Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global GFAP Antibody Sales Value by Application (2021-2032)
  10. 5.2.3 Global GFAP Antibody Sales Value Share by Application (2021-2032)
6 GFAP Antibody Regional Value Analysis
  1. 6.1 Global GFAP Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global GFAP Antibody Sales Value by Region (2021-2032)
  3. 6.2.1 Global GFAP Antibody Sales Value by Region: 2021-2026
  4. 6.2.2 Global GFAP Antibody Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America GFAP Antibody Sales Value (2021-2032)
  7. 6.3.2 North America GFAP Antibody Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe GFAP Antibody Sales Value (2021-2032)
  10. 6.4.2 Europe GFAP Antibody Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific GFAP Antibody Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific GFAP Antibody Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America GFAP Antibody Sales Value (2021-2032)
  16. 6.6.2 South America GFAP Antibody Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa GFAP Antibody Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa GFAP Antibody Sales Value Share by Country, 2025 VS 2032
7 GFAP Antibody Country-level Value Analysis
  1. 7.1 Global GFAP Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global GFAP Antibody Sales Value by Country (2021-2032)
  3. 7.2.1 Global GFAP Antibody Sales Value by Country (2021-2026)
  4. 7.2.2 Global GFAP Antibody Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA GFAP Antibody Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada GFAP Antibody Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico GFAP Antibody Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany GFAP Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France GFAP Antibody Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. GFAP Antibody Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy GFAP Antibody Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain GFAP Antibody Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia GFAP Antibody Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands GFAP Antibody Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries GFAP Antibody Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China GFAP Antibody Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan GFAP Antibody Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea GFAP Antibody Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India GFAP Antibody Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia GFAP Antibody Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia GFAP Antibody Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil GFAP Antibody Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina GFAP Antibody Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile GFAP Antibody Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia GFAP Antibody Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru GFAP Antibody Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia GFAP Antibody Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel GFAP Antibody Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE GFAP Antibody Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey GFAP Antibody Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran GFAP Antibody Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran GFAP Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt GFAP Antibody Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt GFAP Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt GFAP Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck GFAP Antibody Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck GFAP Antibody Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Synaptic Systems
  8. 8.2.1 Synaptic Systems Company Information
  9. 8.2.2 Synaptic Systems Business Overview
  10. 8.2.3 Synaptic Systems GFAP Antibody Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Synaptic Systems GFAP Antibody Product Portfolio
  12. 8.2.5 Synaptic Systems Recent Developments
  13. 8.3 Sino Biological
  14. 8.3.1 Sino Biological Company Information
  15. 8.3.2 Sino Biological Business Overview
  16. 8.3.3 Sino Biological GFAP Antibody Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sino Biological GFAP Antibody Product Portfolio
  18. 8.3.5 Sino Biological Recent Developments
  19. 8.4 Santa Cruz Biotechnology
  20. 8.4.1 Santa Cruz Biotechnology Company Information
  21. 8.4.2 Santa Cruz Biotechnology Business Overview
  22. 8.4.3 Santa Cruz Biotechnology GFAP Antibody Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Santa Cruz Biotechnology GFAP Antibody Product Portfolio
  24. 8.4.5 Santa Cruz Biotechnology Recent Developments
  25. 8.5 Proteintech
  26. 8.5.1 Proteintech Company Information
  27. 8.5.2 Proteintech Business Overview
  28. 8.5.3 Proteintech GFAP Antibody Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Proteintech GFAP Antibody Product Portfolio
  30. 8.5.5 Proteintech Recent Developments
  31. 8.6 ProSci
  32. 8.6.1 ProSci Company Information
  33. 8.6.2 ProSci Business Overview
  34. 8.6.3 ProSci GFAP Antibody Revenue and Gross Margin (2021-2026)
  35. 8.6.4 ProSci GFAP Antibody Product Portfolio
  36. 8.6.5 ProSci Recent Developments
  37. 8.7 Miltenyi Biotec
  38. 8.7.1 Miltenyi Biotec Company Information
  39. 8.7.2 Miltenyi Biotec Business Overview
  40. 8.7.3 Miltenyi Biotec GFAP Antibody Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Miltenyi Biotec GFAP Antibody Product Portfolio
  42. 8.7.5 Miltenyi Biotec Recent Developments
  43. 8.8 Hytest
  44. 8.8.1 Hytest Company Information
  45. 8.8.2 Hytest Business Overview
  46. 8.8.3 Hytest GFAP Antibody Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Hytest GFAP Antibody Product Portfolio
  48. 8.8.5 Hytest Recent Developments
  49. 8.9 GeneTex
  50. 8.9.1 GeneTex Company Information
  51. 8.9.2 GeneTex Business Overview
  52. 8.9.3 GeneTex GFAP Antibody Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GeneTex GFAP Antibody Product Portfolio
  54. 8.9.5 GeneTex Recent Developments
  55. 8.10 FineTest
  56. 8.10.1 FineTest Company Information
  57. 8.10.2 FineTest Business Overview
  58. 8.10.3 FineTest GFAP Antibody Revenue and Gross Margin (2021-2026)
  59. 8.10.4 FineTest GFAP Antibody Product Portfolio
  60. 8.10.5 FineTest Recent Developments
  61. 8.11 Enzo Life Sciences
  62. 8.11.1 Enzo Life Sciences Company Information
  63. 8.11.2 Enzo Life Sciences Business Overview
  64. 8.11.3 Enzo Life Sciences GFAP Antibody Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Enzo Life Sciences GFAP Antibody Product Portfolio
  66. 8.11.5 Enzo Life Sciences Recent Developments
  67. 8.12 EnCor Biotechnology
  68. 8.12.1 EnCor Biotechnology Company Information
  69. 8.12.2 EnCor Biotechnology Business Overview
  70. 8.12.3 EnCor Biotechnology GFAP Antibody Revenue and Gross Margin (2021-2026)
  71. 8.12.4 EnCor Biotechnology GFAP Antibody Product Portfolio
  72. 8.12.5 EnCor Biotechnology Recent Developments
  73. 8.13 Aviva Systems Biology
  74. 8.13.1 Aviva Systems Biology Company Information
  75. 8.13.2 Aviva Systems Biology Business Overview
  76. 8.13.3 Aviva Systems Biology GFAP Antibody Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Aviva Systems Biology GFAP Antibody Product Portfolio
  78. 8.13.5 Aviva Systems Biology Recent Developments
  79. 8.14 Atlas Antibodies
  80. 8.14.1 Atlas Antibodies Company Information
  81. 8.14.2 Atlas Antibodies Business Overview
  82. 8.14.3 Atlas Antibodies GFAP Antibody Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Atlas Antibodies GFAP Antibody Product Portfolio
  84. 8.14.5 Atlas Antibodies Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst